10-Q: ZyVersa Faces Delisting, Impairment Amidst Mounting Losses

ZyVersa Therapeutics reported a significant net loss and an $18.6 million impairment charge, raising substantial doubt about its ability to continue as a going concern following its Nasdaq delisting.

Summary

• Incurred a net loss of $24.3 million for the nine months ended September 30, 2025, a substantial increase from $8.0 million in the prior year period.
• Recorded an $18.6 million impairment charge on in-process research and development (IPR&D) due to a significant decline in market capitalization and challenges in accessing capital.
• Cash balance decreased to $527,978 as of September 30, 2025, from $1,530,924 at December 31, 2024.
• Accumulated deficit grew to $136.9 million as of September 30, 2025.
• Working capital deficiency worsened to $11.8 million from $9.5 million at December 31, 2024.
• The company was delisted from The Nasdaq Capital Market on October 6, 2025, and its common stock now trades on the OTCQB Venture Market.
• Entered into an Equity Purchase Agreement with Williamsburg Venture Holdings, LLC, for up to $10.0 million in common stock sales.
• Completed a warrant inducement offer, generating $2.1 million in cash proceeds but incurring a $1.8 million non-cash warrant modification charge.
• Research and development expenses decreased by $0.6 million (37.6%) to $1.0 million for the nine months ended September 30, 2025.
• General and administrative expenses decreased by $0.9 million (15.1%) to $5.3 million for the nine months ended September 30, 2025.

Sentiment

Score: 2

Explanation: The overall sentiment is highly negative due to a massive net loss driven by a significant impairment charge, a deteriorating cash position, a substantial accumulated deficit, and the company's delisting from Nasdaq. The explicit 'going concern' warning and the challenges in the biotech funding environment further contribute to a very poor outlook, despite some successful, albeit dilutive, financing activities.

Positives

• Net cash used in operating activities decreased to $4.7 million for the nine months ended September 30, 2025, from $6.3 million in the prior year period.
• Successfully raised $3.7 million in financing activities for the nine months ended September 30, 2025, including $2.0 million from a private placement of warrants and $2.1 million from a warrant inducement offer.
• Secured an Equity Purchase Agreement for up to $10.0 million in potential future equity sales.

Negatives

• Reported a significant net loss of $24.3 million for the nine months ended September 30, 2025, a 203.7% increase from $8.0 million in the prior year.
• Incurred an $18.6 million impairment charge on in-process research and development (IPR&D) due to a sustained decline in market capitalization and limited access to capital.
• Cash balance declined to $0.5 million as of September 30, 2025, from $1.5 million at December 31, 2024.
• Accumulated deficit increased to $136.9 million, indicating a history of significant losses.
• Working capital deficiency worsened to $11.8 million from $9.5 million at December 31, 2024.
• Delisted from The Nasdaq Capital Market on October 6, 2025, and now trades on the less liquid OTCQB Venture Market.
• Substantial doubt exists about the company's ability to continue as a going concern for at least one year.
• Reliance on a single vendor for 56% of accounts payable related to critical research and development activities.
• Disputed vendor invoices totaling $1,067,305 for unsupported charges and unaccrued interest, which could become a future liability.

Risks

• Substantial doubt about the ability to continue as a going concern for at least one year from the financial statement issuance date.
• The need to raise additional funds through equity or debt financing, with no assurance of success or commercially acceptable terms.
• Failure to raise capital would negatively impact financial condition and ability to pursue business strategy.
• The company has not yet achieved profitability and may never do so, requiring significant product revenues to offset increasing expenses.
• Delisting from Nasdaq may result in a very limited market for common stock, making it difficult for stockholders to sell shares and adversely affecting trading price and liquidity.
• Uncertainty regarding the nature, timing, and costs of completing product candidate development, including clinical trial duration, patient enrollment, and regulatory approvals.
• Expenditures are subject to uncertainties, including the terms and timing of regulatory approvals and the expense of protecting intellectual property rights.
• Reliance on a single vendor for 56% of accounts payable related to critical research and development, posing a concentration risk.
• Potential future liabilities from disputed vendor invoices totaling $1,067,305, which are currently unaccrued.
• Future equity issuances will dilute existing stockholders.
• Warrants are unlikely to be exercised if the market price of common stock is less than their exercise price, limiting potential cash proceeds from warrant exercises.

Future Outlook

The company expects to continue incurring significant expenses and operating losses for the foreseeable future, requiring additional financing through equity or debt. There is no assurance that adequate financing will be available on acceptable terms, or at all. The company will need to generate significant product revenues to achieve profitability, which it may never do. Development costs for product candidates are expected to be substantial and will take years, with success highly uncertain due to numerous clinical trial and regulatory risks.

Management Comments

• Management believes that the company has access to capital resources and continues to evaluate additional financing opportunities; however, there can be no assurance that it will be successful in securing additional capital or that the company will be able to obtain funds on commercially acceptable terms, if at all.
• There is also no assurance that the amount of funds the company might raise will enable the company to complete its development initiatives or attain profitable operations.
• Management does not expect that our disclosure controls and procedures or our internal control over financial reporting will prevent or detect all errors and fraud.

Industry Context

ZyVersa Therapeutics operates in the highly capital-intensive and risk-prone clinical-stage biopharmaceutical industry. The company's challenges, including significant operating losses, a substantial accumulated deficit, and difficulty accessing capital, reflect a broader risk-averse environment for biotech, characterized by decreased investor appetite for risk, market volatility, and regulatory uncertainty. The impairment of its IPR&D asset underscores the difficulty in financing drug development to key milestones in the current climate. Its delisting from Nasdaq further exacerbates these challenges, moving it to a less liquid market, which is a common struggle for smaller, early-stage biotech firms facing financial distress.

Comparison to Industry Standards

• NA

Legal Proceedings

• The company may be involved in legal proceedings, claims, and assessments arising in the ordinary course of business.
• Disputed vendor invoices totaling $1,067,305 for unsupported charges and unaccrued interest, which the company has requested the vendor to rescind.

Stakeholder Impact

• **Shareholders**: Significant dilution from past and potential future equity issuances, substantial decrease in total equity, delisting from Nasdaq leading to reduced liquidity and potentially adverse trading prices, and substantial doubt about the company's ability to continue as a going concern, posing a high risk of capital loss.
• **Employees/Consultants**: Continued employment and compensation are dependent on the company's ability to secure additional financing and achieve operational success, which is uncertain.
• **Customers (future)**: The development of new drugs for chronic renal or inflammatory diseases is critical for patients with high unmet medical needs, but the company's financial instability puts the successful completion and commercialization of these drugs at risk.
• **Vendors**: One vendor accounts for 56% of accounts payable, indicating significant reliance. Disputed invoices with a vendor could strain relationships and potentially lead to legal action or delayed payments.
• **Creditors**: Increased total liabilities and a worsening working capital deficiency, coupled with going concern doubt, increase the risk for creditors.

Next Steps

• Progress development of VAR 200 and IC 100.
• Prepare and file regulatory submissions for product candidates.
• Begin to manufacture product candidates for clinical trials.
• Hire additional research and development, finance, and general and administrative personnel.
• Protect and defend intellectual property.
• Meet the requirements of being a public company (now on OTCQB).
• Seek additional financing through public or private equity or debt financings or other sources, including government grants and collaborations.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial net loss of $24.3 million, an $18.6 million impairment charge, a rapidly dwindling cash balance of $0.5 million, and a significant accumulated deficit of $136.9 million. The explicit 'substantial doubt' about its ability to continue as a going concern, coupled with its delisting from Nasdaq to the less liquid OTCQB market, signals extreme operational and financial risk. While some financing was secured, it was highly dilutive and insufficient to alleviate the fundamental liquidity crisis. The company's long-term viability is highly questionable, making it an exceptionally risky investment with a high probability of further capital erosion.

Keywords

Biopharmaceutical, Clinical Stage, Renal Disease, Inflammatory Disease, FSGS, Obesity, Cardiometabolic, VAR 200, IC 100, SEC Filing, 10-Q, Nasdaq Delisting, OTCQB, Going Concern, Impairment, Equity Financing, Warrants, Drug Development